Home » Newsletters » BioWorld Science

BioWorld Science

July 3, 2020

View Archived Issues

Boehringer Ingelheim begins home-based phase II study of BI-1358894 for MDD

Shock and kill with less toxicity

MANIFEST study results of CPI-0610 in advanced myelofibrosis set up phase III study

Programmed necrosis has role in post-flu bacterial infections

Meissa completes pre-IND meeting for COVID-19 vaccine candidate MV-014-210

Phase III study of pracinostat plus azacytidine in AML discontinued due to lack of efficacy

LAMC2 identified as a therapeutic target in PDAC

Yuhan discovers semicarbazide-sensitive amine oxidase inhibitors

CREDO 2 pivotal global phase III study of olokizumab meets endpoints

New E-NPP 2 inhibitors identified at Roche

Janssen synthesizes new cyclopentyl nucleoside analogues

Spanish approval granted for COVID-19 study using EnteraGam

Heptares Therapeutics identifies new orexin OX1 receptor antagonists

Lilly patents TYK2 JH2 domain ligands

Phase III trial of Kevzara in COVID-19 does not meet primary and key secondary endpoints

FDA approves Rukobia for the treatment of adults with multidrug-resistant HIV-1 infection

First patient dosed in phase II study of ICP-192 for cholangiocarcinoma

FDA approves Byfavo injection for the induction and maintenance of procedural sedation

IBT-V02: Staphylococcus aureus vaccine that confers protection in mouse and rabbit

SGN-B6A demonstrates promising activity in solid tumor models

Discovery and preclinical evaluation of potent FLT3/AXL dual inhibitor, JR-F104

Neuren begins first-in-human study of oral NNZ-2591 in healthy volunteers

First-in-human study evaluates metarrestin in metastatic solid tumors

COVAX-19 begins phase I study in Australia

Modest activity seen with tislelizumab in phase II lymphoma study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...